London, UK -- (MARKET WIRE) -- January 16, 2007 --
FOR IMMEDIATE RELEASE 16 JANUARY 2007
SkyePharma PLC
CIRCULAR POSTED TODAY TO SHAREHOLDERS
London, England, 16 January, 2007 - SkyePharma PLC (LSE: SKP; NASDAQ: SKYE)
announces that, further to its announcement on 9 January 2007, a Circular, which
details the proposed disposal of its Injectable Business and the proposed
placing with certain institutional investors, will today be posted to
shareholders of the Company.
The Circular includes a notice convening an Extraordinary General Meeting to be
held on 8 February 2007 at 10am at Stringer Saul LLP, First Floor, 17 Hanover
Square, London W1S 1HU at which resolutions will be proposed, inter alia, to
approve the disposal and the issue of shares under the placing.
The Circular will shortly be available for inspection at the UK Listing
Authority's Document Viewing Facility at the Financial Services Authority, 25
The North Colonnade, Canary Wharf, London E14 5HS.
EXPECTED TIMETABLE OF KEY EVENTS
Posting of Circular to Shareholders 16 January 2007
Latest time and date for receipt of 10am on
Forms of Proxy 6 February 2007
Extraordinary General Meeting 10 am on
8 February 2007
Expected date of completion 9 February 2007
of the Disposal
Expected date of Placing 12 February 2007
Shares being admitted
For further information please contact:
SkyePharma PLC +44 207 491 1777
Frank Condella, Chief Executive Officer
Ken Cunningham, Chief Operating Officer
Peter Grant, Finance Director
Buchanan Communications +44 207 466 5000
Tim Anderson / Mark Court / Rebecca Skye Dietrich
Trout Group (US)
Seth Lewis +(1) 617-583-1308
Notes for editors
About SkyePharma
SkyePharma PLC develops pharmaceutical products benefiting from world-leading
drug delivery technologies that provide easier-to-use and more effective drug
formulations. There are now eleven approved products incorporating SkyePharma's
technologies in the areas of oral, injectable, inhaled and topical delivery,
supported by advanced solubilisation capabilities. For more information, visit
www.skyepharma.com.
These materials are not an offer for sale of securities in the United States.
The securities in the placing have not been and will not be registered under the
US Securities Act of 1933 (the "Securities Act") and the securities may not be
sold in the United States absent registration or an exemption from registration
under the Securities Act. The Company does not intend to register any portion of
such offering in the United States or to conduct a public offering of the
ordinary shares in the United States.
The information contained herein does not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of the securities
referred to herein in any jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration, exemption from registration or
qualification under the securities laws of any jurisdiction.
This information is provided by RNS
The company news service from the London Stock Exchange